agilon doesn't have a cash problem. It has a *trust problem* — and that's what 2026 will work on.
↓ scroll to read
✦ The bottom line
agilon ended Q1 2026 with $303M in cash and marketable securities, against just $32M of total debt. Adjusted EBITDA hit $54M — 162% higher than Q1 2025. Net income was $49M. The company is no longer in survival mode; it's in prove-it mode.
↓ the brief below
✦ Teach me
Why 'medical loss ratio' is the only number that matters here
For value-based providers like agilon, the single most important operating ratio is medical loss ratio — what percentage of premium dollars get spent on actual healthcare. If agilon collects $1,000 per member per month and spends $900 on care, the medical loss ratio is 90% and they keep $100 to cover operations. In 2024-25, medical loss ratios spiked beyond expectations — utilization rose, drug prices rose, and agilon's contracts didn't have enough cushion. Q1 2026's improved medical margin says the underwriting is finally pricing in those higher costs.
Wall Street calls this
MLR / medical loss ratio
If the medical margin stays stable while membership re-grows, agilon's economics work. If MLR spikes again, the model is in trouble again.
The cushion · cash position
$303
M
Cash and marketable securities of $303M against total debt of only $32M — a strong balance sheet for a company that was financially stressed two years ago.
Source · 8-K · Item 2.02 — Capital Position and Balance Sheet · Q1 2026 · Filed May 6, 2026
The bigger signal was guidance. Management raised full-year 2026 expectations across the board: revenue $5.68-5.81B (up from $5.41-5.58B), medical margin $350-400M (up from $300-350M), adjusted EBITDA $10-40M (up from -$15 to $15M). The midpoint of the EBITDA range moved from breakeven to clearly positive.
The commitment · raised FY guidance
$10-40
M EBITDA
FY2026 Adjusted EBITDA guidance raised to $10-40M (from -$15 to $15M) — first time agilon is publicly committing to clearly positive operating performance.
Source · 8-K · Item 2.02 — Second Quarter and Revised FY2026 Guidance · Q1 2026 · Filed May 6, 2026
⚠
Watch
Real financial improvement and raised guidance — but the model has surprised investors before, in both directions.